More countries delay use of Johnson & Johnson vaccine 

New York, April 14 (RHC)-- The European rollout of the Johnson & Johnson vaccine has been delayed after regulators in the United States moved to temporarily halt its use as reports of extremely rare blood clots were being investigated.  South Africa also suspended its use of the Johnson & Johnson vaccine. 

Six women, aged 18 to 48, reported the clots after receiving the shot, and one has died.  The number represents less than one in a million administered J&J shots in the U.S., and it’s not yet known if the condition is linked to the vaccine.  What is known is the standard treatment of blood clots — Heparin — is contraindicated for this reaction.